U.S. Chrysalis lead compound TP508 is qualified by FDA and EJEC orphan drug
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, according to foreign media reports, the U.Sbio
pharmaceutical(http://company(http://Chrysalis BioTherapeutics announced that its lead compound TP508 wasfda(http://and the EuropeanDrug(http://Administration (EMA) orphan drug eligibility for the treatment of acute radiation syndrome (ARS)About TP508
TP508 is a natural clotting enzyme polypeptidedrug(http:// developed based on regenerative medicine to mitigate the effects of cancer radiotherapy on the body TP508 has anti-inflammatory and anti-apoptosis effects, protects tissue cells and stimulates multiple tissues for self-healing The clinical trial (http:// of human tissue repair has been proven to be safe and effective TP508 was originally used to treat skin and musculoskeletal damage early human clinical trials have shown that TP508 drugs are particularly effective in promoting diabetic foot ulcer healing and can be handled in patients with mass casualties and severe burns
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
